Literature DB >> 9342229

Type-1 plasminogen-activator inhibitor -- conformational differences between latent, active, reactive-centre-cleaved and plasminogen-activator-complexed forms, as probed by proteolytic susceptibility.

R Egelund1, S L Schousboe, L Sottrup-Jensen, K W Rodenburg, P A Andreasen.   

Abstract

We have analysed the susceptibility of latent, active, reactive-centre-cleaved and plasminogen-activator-complexed type-1 plasminogen-activator inhibitor (PAI-1) to the non-target proteinases trypsin, endoproteinase Asp-N, proteinase K and subtilisin. This analysis has allowed us to detect conformational differences between the different forms of PAI-1 outside the reactive-centre loop and beta-sheet A. Proteinase-hypersensitive sites were clustered in three regions. Firstly, susceptibility was observed in the region around alpha-helix E, beta-strand 1A, and the flanking loops, which are believed to form flexible joints during movements of beta-sheet A. Secondly, hypersensitive sites were observed in the loop between alpha-helix I and beta-strand 5A. Thirdly, the gate region, encompassing beta-strands 3C and 4C, was highly susceptible to trypsin in latent PAI-1, but not in the other conformations. The digestion patterns differed among all four forms of PAI-1, indicating that each represents a unique conformation. The differential proteolytic susceptibility of the flexible-joint region may be coupled to the differential affinity to vitronectin, binding in the same region. The analysis also allowed detection of conformational differences between reactive-centre-cleaved forms produced under different solvent conditions. The digestion pattern of plasminogen-activator-complexed PAI-1 was different from that of active PAI-1, but indistinguishable from that of one of the reactive-centre-cleaved forms, as the complexed and this particular cleaved PAI-1 were completely resistant to all the non-target proteinases tested. This observation is in agreement with the notion that complex formation involves reactive-centre cleavage and a large degree of insertion of the reactive-centre loop into beta-sheet A. Our analysis has allowed the identification of some flexible regions that appear to be implicated in the conformational changes during the movements of beta-sheet A and during the inhibitory reaction of serpins with their target proteinases.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9342229     DOI: 10.1111/j.1432-1033.1997.t01-1-00775.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  10 in total

1.  Comparison between the clot-protecting activity of a mutant plasminogen activator inhibitor-1 with a very long half-life and 6-aminocaproic acid.

Authors:  Daniel Glenn Kindell; Rick Wayne Keck; Jerzy Jankun
Journal:  Exp Ther Med       Date:  2015-04-01       Impact factor: 2.447

2.  Binding of urokinase-type plasminogen activator-plasminogen activator inhibitor-1 complex to the endocytosis receptors alpha2-macroglobulin receptor/low-density lipoprotein receptor-related protein and very-low-density lipoprotein receptor involves basic residues in the inhibitor.

Authors:  K W Rodenburg; L Kjoller; H H Petersen; P A Andreasen
Journal:  Biochem J       Date:  1998-01-01       Impact factor: 3.857

3.  The length of the reactive center loop modulates the latency transition of plasminogen activator inhibitor-1.

Authors:  Yu-Ran Na; Hana Im
Journal:  Protein Sci       Date:  2004-12-02       Impact factor: 6.725

4.  Biochemical mechanism of action of a diketopiperazine inactivator of plasminogen activator inhibitor-1.

Authors:  Anja P Einholm; Katrine E Pedersen; Troels Wind; Paulina Kulig; Michael T Overgaard; Jan K Jensen; Julie S Bødker; Anni Christensen; Peter Charlton; Peter A Andreasen
Journal:  Biochem J       Date:  2003-08-01       Impact factor: 3.857

5.  Single fluorescence probes along the reactive center loop reveal site-specific changes during the latency transition of PAI-1.

Authors:  Tihami Qureshi; Cynthia B Peterson
Journal:  Protein Sci       Date:  2015-11-25       Impact factor: 6.725

6.  Plasminogen activator inhibitor-1 polymers, induced by inactivating amphipathic organochemical ligands.

Authors:  Katrine E Pedersen; Anja P Einholm; Anni Christensen; Lotte Schack; Troels Wind; John M Kenney; Peter A Andreasen
Journal:  Biochem J       Date:  2003-06-15       Impact factor: 3.857

7.  Prognostic value of tissue-type plasminogen activator (tPA) and its complex with the type-1 inhibitor (PAI-1) in breast cancer.

Authors:  J H de Witte; C G Sweep; J G Klijn; N Grebenschikov; H A Peters; M P Look; T H van Tienoven; J J Heuvel; J Bolt-De Vries; T J Benraad; J A Foekens
Journal:  Br J Cancer       Date:  1999-04       Impact factor: 7.640

8.  Plasminogen activator inhibitor 1 may promote tumour growth through inhibition of apoptosis.

Authors:  H C Kwaan; J Wang; K Svoboda; P J Declerck
Journal:  Br J Cancer       Date:  2000-05       Impact factor: 7.640

9.  Conformational preludes to the latency transition in PAI-1 as determined by atomistic computer simulations and hydrogen/deuterium-exchange mass spectrometry.

Authors:  Michael Petersen; Jeppe B Madsen; Thomas J D Jørgensen; Morten B Trelle
Journal:  Sci Rep       Date:  2017-07-26       Impact factor: 4.379

10.  Resolving distinct molecular origins for copper effects on PAI-1.

Authors:  Joel C Bucci; Carlee S McClintock; Yuzhuo Chu; Gregory L Ware; Kayla D McConnell; Joseph P Emerson; Cynthia B Peterson
Journal:  J Biol Inorg Chem       Date:  2017-09-14       Impact factor: 3.358

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.